Literature DB >> 14690246

A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity.

Michael Adler1, Harlan F Shafer, Heather A Manley, Brennie E Hackley, James D Nicholson, James E Keller, Michael C Goodnough.   

Abstract

Botulinum neurotoxin B (BoNT/B) produces muscle paralysis by cleaving synaptobrevin/vesicle-associated membrane protein (VAMP), an 18-kDa membrane-associated protein located on the surface of small synaptic vesicles. A capillary electrophoresis (CE) assay was developed to evaluate inhibitors of the proteolytic activity of BoNT/B with the objective of identifying suitable candidates for treatment of botulism. The assay was based on monitoring the cleavage of a peptide that corresponds to residues 44-94 of human VAMP-2 (V51) following reaction with the catalytic light chain (LC) of BoNT/B. Cleavage of V51 generated peptide fragments of 18 and 33 amino acids by scission of the bond between Q76 and F77. The fragments and parent peptide were clearly resolved by CE, allowing accurate quantification of the BoNT/B LC-mediated reaction rates. The results indicate that CE is suitable for assessing the enzymatic activity of BoNT/B LC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14690246     DOI: 10.1023/b:jopc.0000005459.00492.60

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  17 in total

1.  High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F.

Authors:  J J Schmidt; R G Stafford; C B Millard
Journal:  Anal Biochem       Date:  2001-09-01       Impact factor: 3.365

2.  'Ringer" solutions and some notes on the physiological basis of their ionic composition.

Authors:  A P LOCKWOOD
Journal:  Comp Biochem Physiol       Date:  1961-04

3.  Botulinum toxin type B in the treatment of cervical dystonia: a pilot study.

Authors:  J K Tsui; M Hayward; E K Mak; M Schulzer
Journal:  Neurology       Date:  1995-11       Impact factor: 9.910

4.  Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.

Authors:  K Jung; M Lein; B Brux; P Sinha; D Schnorr; S A Loening
Journal:  Clin Chem Lab Med       Date:  2000-12       Impact factor: 3.694

5.  SNARE function analyzed in synaptobrevin/VAMP knockout mice.

Authors:  S Schoch; F Deák; A Königstorfer; M Mozhayeva; Y Sara; T C Südhof; E T Kavalali
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

6.  Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments.

Authors:  P Foran; C C Shone; J O Dolly
Journal:  Biochemistry       Date:  1994-12-27       Impact factor: 3.162

7.  Human type A botulism and treatment with 3,4-diaminopyridine.

Authors:  L E Davis; J K Johnson; J M Bicknell; H Levy; K M McEvoy
Journal:  Electromyogr Clin Neurophysiol       Date:  1992 Jul-Aug

8.  Clostridial neurotoxins: new tools for dissecting exocytosis.

Authors:  H Niemann; J Blasi; R Jahn
Journal:  Trends Cell Biol       Date:  1994-05       Impact factor: 20.808

9.  Clues to the multi-phasic inhibitory action of botulinum neurotoxins on release of transmitters.

Authors:  J O Dolly; A C Ashton; C McInnes; J D Wadsworth; B Poulain; L Tauc; C C Shone; J Melling
Journal:  J Physiol (Paris)       Date:  1990

10.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.

Authors:  G Schiavo; F Benfenati; B Poulain; O Rossetto; P Polverino de Laureto; B R DasGupta; C Montecucco
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

View more
  2 in total

1.  A two-stage multiplex method for quantitative analysis of botulinum neurotoxins type A, B, E, and F by MALDI-TOF mass spectrometry.

Authors:  Dongxia Wang; Jakub Baudys; Joan Krilich; Theresa J Smith; John R Barr; Suzanne R Kalb
Journal:  Anal Chem       Date:  2014-10-20       Impact factor: 6.986

2.  Synthetic substrate for application in both high and low throughput assays for botulinum neurotoxin B protease inhibitors.

Authors:  Nicholas T Salzameda; Joseph T Barbieri; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2009-08-27       Impact factor: 2.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.